CAS: 90-69-7; (-)-Lobeline
- ⚠️《化妆品禁用原料目录》
- 英文名称(-)-Lobeline
- 中文名称洛贝林
- IUPAC名称2-((2S,6R)-6-((S)-2-hydroxy-2-phenylethyl)-1-methylpiperidin-2-yl)-1-phenylethan-1-one
- 其它别名Ethanone,2-[6-(2-hydroxy-2-phenylethyl)-1-methyl-2-piperidinyl]-1-phenyl-, [2R-[2a,6a(S*)]]-; Lobeline (8CI); a-Lobeline (7CI); (-)-Lobeline; (-)-a-Lobeline; 2-[6-(b-Hydroxyphenethyl)-1-methyl-2-piperidyl]acetophenone; 8,10-Diphenyllobelionol; Inflatine; L-Lobeline; Lobelin; Lobnico; l-Lobeline
- CAS编号90-69-7
- MFCD编号:MFCD00056052
- EINECS号:202-012-3
- FDA UNII编号:D0P25S3P81
- 分子式:C22H27NO2分子量:337.46
- 产品CID: 1940612
- 产品分类原料药 → 神经系统用药 → 中枢兴奋药
物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS06;
注释: Skull and crossbones - 危险类别急性毒性 类别3(吸入)
急性毒性 类别3(经皮)
急性毒性 类别3(经口) - 警示词Danger(危险)
- 危险描述H331 |吸入会中毒.
H311 |皮肤接触会中毒.
H301 |吞咽会中毒. - 防范说明P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501
- 危险等级6.1(b)
- UN编号1544
- 危险品标志T
- 包装等级III
- 安全声明36/37/39-45
- 危险类别码23/24/25
欧盟法规
ECHA物质ECHA物质化妆品禁用物质清单C&L通报REACH预注册上下游产品
CAS号134-63-4 盐酸洛贝林 | CAS号6919-61-5 N-甲基-N-甲基苯甲酰胺 | CAS号6249-80-5 4-Phenyl-1-bute... | CAS号80735-94-0 1-苯基-3-丁烯-1-醇 | CAS号85551-57-1 (αR)-α-(2-prope... | CAS号423763-79-5 (1R,3S)-2-oxira... | CAS号423763-78-4 (4S,6R)-4-iodom... | CAS号423763-77-3 tert-butyl [(1R...合成工艺路线路线简述
📜Lobelanine置于甲酸铵体系中,用 1,2-二氯乙烷 作为反应溶剂,化学反应 1.0H,以91%的收率获得产物洛贝林
参考文献:2-[(2R,6S)-6-[(2S)-2-羟基-2-苯乙基]-1-甲基哌啶]-1-苯乙酮的合成方法
标题:2-[(2R,6S)-6-[(2S)-2-羟基-2-苯乙基]-1-甲基哌啶]-1-苯乙酮的合成方法
摘要:本发明公开了2‑[(2R,6S)‑6‑[(2S)‑2‑羟基‑2‑苯乙基]‑1‑甲基哌啶]‑1‑苯乙酮的合成方法,属于有机合成领域.本发明先采用(1S,2S)‑1,2‑二苯基乙二胺为原料经过酰化,取代等三步制备手性胺催化剂;主路线总共两步,采用戊二醛,苯甲酰乙酸,甲胺盐酸盐合成出顺式山梗烷酮,在催化剂的作用下,通过温和的反应条件进行不对称选择性还原合成2‑[(2R,6S)‑6‑[(2S)‑2‑羟基‑2‑苯乙基]‑1‑甲基哌啶]‑1‑苯乙酮.整个工艺路线原料便宜易得,催化剂可以回收继续利用,成本低,工艺简单,反应条件温和,操作方便,总收率高.
海关参考信息
- 2902600000-乙苯
2905121000-正丙醇
2905130000-正丁醇
2906210000-苄醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12291505-B2
优先权日:2016-07-04
标题 :Methods for the synthesis of deuterated dextromethorphan
发明人：JOHNSON MATT; ZHAO CUNXIANG; MENG WEIHUA; LU ZHIJUN; LI YAN
权利人:AVANIR PHARMACEUTICALS INC
摘要:The application describes methods for making a deuterated dextromethorphan of Formula (I), deuterated dextromethorphan produced by these methods, and pharmaceutically acceptable salts thereof.
专利号:US-2024124402-A1
优先权日:2016-07-04
标 题:Methods for the synthesis of deuterated dextromethorphan
专利号:US-2024067608-A1
优先权日:2016-07-04
标 题:Methods for the synthesis of deuterated dextromethorphan
专利号:US-8252930-B2
优先权日:2006-07-06
标 题:Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
发明人：STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G
权利人:STOIT AXEL; COOLEN HEIN K A C; VAN DER NEUT MARTINA A W; KRUSE CORNELIS G; SOLVAY PHARM BV
摘要:Azaindole derivatives of formula (I): n nwherein the symbols have the meanings given in the specification, are described. These compounds have a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition. The invention also relates to pharmaceutical compositions containing these compounds, to methods for preparing them, methods for preparing novel intermediates useful for their synthesis, methods for preparing compositions, and uses of such compounds and compositions, for example, their use in administering them to patients to achieve a therapeutic effect in disorders in which nicotinic receptors and/or dopamine transporters are involved, or that can be treated via manipulation of those receptors.
专利号:EP-3478664-B1
优先权日:2016-07-04
标题 :Methods for the synthesis of deuterated dextromethorphan
专利号:US-2019241525-A1
优先权日:2016-07-04
标题:Methods for the synthesis of deuterated dextromethorphan
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Zheng G, Crooks PA. Synthesis of Lobeline, Lobelane and their Analogues. A Review. Org Prep Proced Int. 2015;47(5):317-337.
2: Li KC, Ho YL, Chen CY, Hsieh WT, Chang YS, Huang GJ. Lobeline improves acute lung injury via nuclear factor-κB-signaling pathway and oxidative stress. Respir Physiol Neurobiol. 2016 May;225:19-30. doi: 10.1016/j.resp.2015.12.003. doi: 10.1016/j.pbb.2015.10.006. doi: 10.1002/jms.3581. doi: 10.1016/j.biocel.2015.03.003. doi: 10.1016/j.neulet.2014.10.009. doi: 10.1016/j.ejphar.2014.05.057. doi: 10.1016/j.lfs.2014.03.034. doi: 10.1007/s00213-014-3472-y.
11: Verde Rodrigues LC, Decker N, Picada JN, Pereira P. Neurotoxicological profile assessment of lobeline after acute treatment in mice. Basic Clin Pharmacol Toxicol. 2014 Jun;114(6):485-9. doi: 10.1111/bcpt.12189.
合成参考文献
参考文献:10.1016/j.jmgm.2011.06.008
摘要:Taly A, Colas C, Malliavin T, Blondel A, Nilges M, Corringer P, Joseph D. Discrimination of agonists versus antagonists of nicotinic ligands based on docking onto AChBP structures. Journal of Molecular Graphics and Modelling. 2011 Sep;30():100–9. doi: 10.1016/j.jmgm.2011.06.008.
参考文献:10.1124/jpet.111.184770
摘要:Horton DB, Siripurapu KB, Zheng G, Crooks PA, Dwoskin LP. Novel N-1,2-Dihydroxypropyl Analogs of Lobelane Inhibit Vesicular Monoamine Transporter-2 Function and Methamphetamine-Evoked Dopamine Release. The Journal of Pharmacology and Experimental Therapeutics. 2011 Oct;339(1):286–97. doi: 10.1124/jpet.111.184770.
📝 需求与反馈
尽可能描述清楚需求与问题信息
